Citations

Clear

89 citation(s) found for "Davis, John".

Longitudinal Occurrence and Predictors of Patient‐Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis: A Case–Control Study
Challa, Divya N. V., Kvrgic, Zoran, Crowson, Cynthia S. , Matteson, Eric L. , Mason, Thomas G. , Michet, Clement J. , Wright, Kerry , Davis, John M. , Schaffer, Daniel E, Wright, Kerry A, Davis, John M , Mason, Thomas G., Schäffer, Daniel E.

Mayo Clinic

Arthritis Care & Research | November 30, 2018 | Volume: 72 | Issue: 1 | Pages: 18-26

10.1002/acr.23819 | PMID 30506552 Get It

ObjectiveTo identify longitudinal predictors of discordance between patients with rheumatoid arthritis (RA) and their health care providers, where patient global assessment of disease activity is substantially higher than provider global assessment.MethodsThis retrospective case–control study included 102 cases with positive discordance (i.e., ≥25 mm between patient and provider global assessments) and 102 controls without discordance who were matched for age, sex, RA duration, and Clinical Disease Activity Index (CDAI) score. Data were collected at the baseline visit (date of diagnosis or earliest available visit), the index visit (participation in a previous cross‐sectional study), and at up to 11 additional visits before the index visit. Data included patient characteristics, disease activity measures, Disease Activity Score in 28 joints (3‐variable) using the C‐reactive protein level (DAS28‐CRP), and medications. Data were analyzed by using linear and logistic regression models with smoothing splines for nonlinear trends.ResultsOverall, the mean age was 63 years, 75% of patients were female, and the mean RA duration was 10 years. Compared with controls, cases had higher rates of discordant visits during the 4 years before the index visit, and they had a higher CDAI score and DAS28‐CRP earlier in the disease course. Cases more frequently had antinuclear antibodies, nonerosive disease, prior depression, or prior use of antidepressants or fibromyalgia medications. Disease‐modifying medication use was not different between cases and controls.ConclusionThe findings inform new hypotheses about the relationships of disease activity and antinuclear antibodies to the later occurrence of positive discordance among patients with RA.
An Increased Abundance of Clostridiaceae Characterizes Arthritis in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Cross-sectional Study
Pedrogo, David A. Muñiz , Hillmann, Benjamin , Jeraldo, Patricio , Davis, John M. , Knights, Dan , Nelson, Heidi , Faubion, William A. , Raffals, Laura E. , Kashyap, Purna , Muniz Pedrogo, David A, Taneja, Veena , Raffals, Laura, Jeraldo, Patricio R , Davis, John M , Chen, Jun , Al‐Ghalith, Gabriel A.

Mayo Clinic

Inflammatory Bowel Diseases | October 12, 2018 | Volume: 25 | Issue: 5 | Pages: 902-913

10.1093/ibd/izy318 | PMID 30321331 Get It

Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk.
Santiago‐Jiménez, María , Davis, John W. , Dicker, Adam P. , Pollack, Alan , Ross, Ashley E. , Plessis, Marguerite du, Choeurng, Voleak, Yousefi, Kasra, Haddad, Zaid , Weinmann, Sheila , Karnes, R. Jeffrey , Feng, Felix Y. , Dicker, Adam P , Spratt, Daniel E. , Zhang, Jingbin , Den, Robert B. , Kane, Christopher J. , Davicioni, Elai , Schaeffer, Edward M. , Klein, Eric A. , Nguyen, Paul L.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 5000-5000

10.1200/jco.2017.35.15_suppl.5000 Get It

5000 Background: It is clinically challenging to integrate genomic classifier results that report a continuous numerical risk of recurrence into treatment decisions for prostate cancer (PCa). We aimed to develop a novel clinical-genomic risk system that can readily be incorporated into treatment guidelines for localized PCa. Methods: Four multi-center cohorts (n = 6928 men; 5937 prospective samples and 991 retrospective samples with long-term follow-up) were utilized to identify and validate our clinical-genomic risk system in radical prostatectomy (RP) samples and subsequently in pre-treatment biopsy samples. All patients’ FFPE tissue underwent microarray analysis, and the expression values for 22 prespecified biomarkers that constitute Decipher were extracted. Cumulative incidence curves were constructed to estimate metastasis risk. C-indices were calculated to compare NCCN and CAPRA score to our clinical-genomic system. Results: With a median follow-up of 8 years for men in our RP cohort, the 10-year distant metastasis rates for NCCN low, favorable-intermediate, unfavorable-intermediate, and high-risk were 7.8%, 9.4%, 40.1%, and 41.4%, respectively. Our 3-tier clinical-genomic risk groups had 10-year distant metastasis rates of 3.7%, 30.7%, and 57.7%, for low, intermediate, and high-risk, which were validated in our pre-treatment biopsy cohort with 10-year rate of distant metastasis of 0%, 30.3%, and 63.2%, respectively. C-indices for the clinical-genomic system (0.84, 95%CI 0.62-0.92) were significantly improved over NCCN (0.71, 95%CI 0.59-0.84) and CAPRA (0.71, 95%CI 0.60-0.81) score. A total of 33.4% of men would be reclassified by the clinical-genomic system, and specifically 17.1%, 41.3%, and 19.4% of men in NCCN low, intermediate and high risk groups would be reclassified by our new system. Conclusions: The use of a readily available genomic classifier in combination with clinicopathologic variables can generate a simple to use 3-tier clinical-genomic risk system that is highly prognostic for distant metastasis, is more accurate than clinical risk, and can be easily incorporated into NCCN guidelines to inform treatment decisions.
Validation of a genomic risk classifier to predict metastasis and prostate cancer-specific mortality in men with positive lymph nodes.
Karnes, R. Jeffrey , Davis, John W. , Haddad, Zaid , Yousefi, Kasra, Ross, Ashley E. , Trock, Bruce J , Claessens, Frank , Davicioni, Elai

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: 125-125

10.1200/jco.2018.36.6_suppl.125 Get It

125 Background: Men with lymph node involvement (LNI) at prostatectomy (RP) are at high risk of dying from prostate cancer. However, survival following RP is highly variable, with some men apparently cured. Nomograms developed for men with LNI have been based on series where all or the vast majority of men received adjuvant treatment. Because administration of adjuvant treatment is not universal, even for LNI, we evaluated whether the Decipher genomic classifier (GC) can improve upon clinical models to predict metastasis within 5 years (MET5) and prostate cancer specific mortality within 10 years (PCSM10) in a cohort of LNI patients, the majority of whom did not receive adjuvant treatment. Methods: 141 patients from 4 institutions (Johns Hopkins, Mayo Clinic, Leuven, MD Anderson) had LNI at RP, had adequate tissue and clinical data for analysis of MET5, and 86 were analyzed for PCSM10. 43% of men received adjuvant therapy. RP tumor tissue was analyzed by Affymetrix Human Exon 1.0 ST GeneChip; the GC was calculated based on 22 genes in the previously trained and validated algorithm. Logistic regression evaluated whether the GC, dichotomized as high risk (GC score > 0.6) vs low-intermediate risk (≤0.6), improved prediction of MET5 and PCSM10 beyond that achieved with established clinical prognostic factors. Results: 62 men (43%) developed MET5, and 35 (41%) developed PCSM10. For both MET5 and PCSM10 CAPRA-S, number of positive lymph nodes, and age were significant; adjuvant therapy was not significant. GC was a significant independent strong prognostic factor when added to the clinical model for prediction of MET5, odds ratio = 4.04 (95% CI: 1.48, 11.02), p = 0.006, and prediction of PCSM10, odds ratio = 6.71 (95% CI: 2.01, 22.38), p = 0.002. Addition of GC to the clinical model improved the AUC from 0.77 to 0.79 for MET5, and from 0.65 to 0.74 for PCSM10. Conclusions: The Decipher GC significantly improves upon clinical variables to predict metastasis and prostate cancer specific mortality in men at high risk due to LNI. This is the first study to show a genomic classifier predicts outcomes in men with LNI; validation is needed to determine if Decipher can improve treatment decisions in men with LNI.
“Like No One Is Listening to Me”: A Qualitative Study of Patient–Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis
Kvrgic, Zoran, Asiedu, Gladys B. , Crowson, Cynthia S. , Ridgeway, Jennifer L. , Davis, John M. , Ridgeway, Jennifer L , Davis, John M

Mayo Clinic

Arthritis Care & Research | December 20, 2017 | Volume: 70 | Issue: 10 | Pages: 1439-1447

10.1002/acr.23501 | PMID 29266857 Get It

ObjectiveTo explore the perspectives and experiences of patients with rheumatoid arthritis (RA) whose assessments of their disease differ from those of their rheumatology care provider.MethodsA total of 20 adult RA patients with patient‐provider discordance at their most recent rheumatology appointment (within 4 weeks) were recruited. Discordance was defined by an absolute difference of 25 or more between patient and provider global assessments on a visual analog scale (VAS) of disease activity. For descriptive purposes, participants completed the Health Assessment Questionnaire II, pain VAS, and Patient Health Questionnaire 9 depression scale. Interviews were conducted in person and individually with each patient with a semistructured interview guide. Topics ranged widely, including participants’ perspectives and experiences with living with RA, clinical disease assessments, patient‐provider communication, and psychosocial or other needs. Data from the interviews were analyzed using interpretive phenomenological analysis.ResultsSix major themes emerged from the patient interviews describing patient‐provider discordance and disease assessment: being misunderstood by others, limitations of provider assessments, discrepancy with provider findings, inadequate active listening on the part of health care providers, unmet psychosocial needs, and lack of patient empowerment.ConclusionPatients described discordance in terms of symptom assessment and understanding how RA affects everyday life. Typical clinical assessments did not capture their experience. The resulting conceptual framework should inform future interventional studies seeking to enhance concordance of patient‐physician communication and to optimize satisfaction with care and health‐related quality‐of‐life outcomes for patients with RA.
Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
Ji, Xuemei , Ciavatta, Dominic J. , Pinder, Benjamin D. , Zhao, Ai, Zhang, Jinyi , Tadesse, Yohannes, Qian, David C. , Nair, Rajan P. , Tsoi, Lam C. , Carette, Simon , Cuthbertson, David , Davis, John C. , Dellaripa, Paul F., Forbess, Lindsy, Gewurz‐Singer, Ora, Hoffman, Gary S., Koening, Curry L. , Langford, Carol A. , Mahr, Alfred , McAlear, Carol A. , Moreland, Larry W. , Seo, Philip , Sreih, Antoine G. , Clair, E. William St. , Stone, John H., Ytterberg, Steven R. , Elder, James T. , Qu, Jia , Ochi, Toshiki , Hirano, Naoto , Edberg, Jeffrey C., Falk, Ronald J. , Siminovitch, Katherine A. , Merkel, Peter A. , Xie, Gang , Monach, Paul A. , Byun, Jinyoung , Weirauch, Matthew T. , Pagnoux, Christian , Chung, Sharon A. , Dellaripa, Paul F. , Khalidi, Nader , Specks, Ulrich , Spiera, Robert , Amos, Christopher I. , Mahr, Alfred , Moreland, Larry W , Tsoi, Lam C

Mayo Clinic

Arthritis & Rheumatology | December 28, 2016 | Volume: 69 | Issue: 5 | Pages: 1054-1066

10.1002/art.40034 | PMID 28029757 Get It

Objective To identify risk alleles relevant to the causal and biologic mechanisms of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). Methods A genome‐wide association study and subsequent replication study were conducted in a total cohort of 1,986 cases of AAV (patients with granulomatosis with polyangiitis [Wegener's] [GPA] or microscopic polyangiitis [MPA]) and 4,723 healthy controls. Meta‐analysis of these data sets and functional annotation of identified risk loci were performed, and candidate disease variants with unknown functional effects were investigated for their impact on gene expression and/or protein function. Results Among the genome‐wide significant associations identified, the largest effect on risk of AAV came from the single‐nucleotide polymorphism variants rs141530233 and rs1042169 at the HLA–DPB1 locus (odds ratio [OR] 2.99 and OR 2.82, respectively) which, together with a third variant, rs386699872, constitute a triallelic risk haplotype associated with reduced expression of the HLA–DPB1 gene and HLA–DP protein in B cells and monocytes and with increased frequency of complementary proteinase 3 (PR3)–reactive T cells relative to that in carriers of the protective haplotype. Significant associations were also observed at the SERPINA1 and PTPN22 loci, the peak signals arising from functionally relevant missense variants, and at PRTN3 , in which the top‐scoring variant correlated with increased PRTN3 expression in neutrophils. Effects of individual loci on AAV risk differed between patients with GPA and those with MPA or between patients with PR3‐ANCAs and those with myeloperoxidase‐ANCAs, but the collective population attributable fraction for these variants was substantive, at 77%. Conclusion This study reveals the association of susceptibility to GPA and MPA with functional gene variants that explain much of the genetic etiology of AAV, could influence and possibly be predictors of the clinical presentation, and appear to alter immune cell proteins and responses likely to be key factors in the pathogenesis of AAV.
No dantrolene protection in a dog model of complete cerebral ischaemia
Kross, John F., Fleischer, Jerry E., Milde, James H., Gronert, Gerald A.

Mayo Clinic

Neurological Research | July 23, 2016 | Volume: 15 | Issue: 1 | Pages: 37-40

10.1080/01616412.1993.11740104 | PMID 8098851 Get It

Editorial: The Multi‐Biomarker Disease Activity Test for Rheumatoid Arthritis: Is It a Valid Measure of Disease Activity?
Davis, John M. , Davis, John M

Mayo Clinic

Arthritis & Rheumatology | April 25, 2016 | Volume: 68 | Issue: 9 | Pages: 2061-2066

10.1002/art.39716 | PMID 27111349 Get It

Time Trends in Glucocorticoid Use in Rheumatoid Arthritis: Results From a Population‐Based Inception Cohort, 1980–1994 Versus 1995–2007
Makol, Ashima , Davis, John M. , Crowson, Cynthia S. , Therneau, Terry M. , Gabriel, Sherine E., Matteson, Eric L. , Davis, John M , Makol, Ashima

Mayo Clinic

Arthritis Care & Research | May 12, 2014 | Volume: 66 | Issue: 10 | Pages: 1482-1488

10.1002/acr.22365 | PMID 24821680 Get It

ObjectiveTo examine trends in glucocorticoid (GC) use and dosing among patients diagnosed with rheumatoid arthritis (RA) over time.MethodsA population‐based inception cohort of RA patients diagnosed during 1980–2007 was followed longitudinally through their medical records until death, migration, or December 31, 2008. GC start and stop dates were collected, along with doses in prednisone equivalents.ResultsThe study population comprised 349 patients (68% women) diagnosed in 1980–1994 and 464 (69% women) diagnosed in 1995–2007, with a median followup of 15.3 and 5.7 years, respectively. A higher proportion of patients started GCs in their first year of disease in 1995–2007 (68% versus 36%; P < 0.001), but the starting dose (mean 8.7 versus 10.3 mg; P = 0.08) and cumulative dose in the first year of use (mean 1.8g [mean daily dose 4.9 mg] versus 2.1 gm [mean daily dose 5.8 mg]; P = 0.48) were not different. A higher proportion also discontinued GCs in their first year of disease in the 1995–2007 cohort (P < 0.001). These differences in GC initiation and discontinuation persisted throughout followup. Prevalence of GC use was higher in the 1995–2007 cohort for the first 3 years of disease.ConclusionMore patients are starting GCs early in their disease course now compared to previously, which is consistent with established treatment guidelines. A higher proportion are also discontinuing GCs, but the proportion of patients taking GCs at any given point of disease during the first 4 years is higher now than previously. Despite early addition of a disease‐modifying antirheumatic drug, some patients may not be able to discontinue GCs over the long term.
Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's)
Tómasson, Gunnar , Davis, John C. , Hoffman, Gary S., McCune, W. Joseph, Clair, E. William St. , Stone, John H. , Specks, Ulrich , Spiera, Robert , Merkel, Peter A.

Mayo Clinic

Arthritis & Rheumatology | October 31, 2013 | Volume: 66 | Issue: 2 | Pages: 428-432

10.1002/art.38248 | PMID 24504815 Get It

ObjectiveTo 1) describe the distribution of patient global assessment (PtGA) scores of disease activity in patients with granulomatosis with polyangiitis (GPA; Wegener's), 2) explore the discordance between PtGA scores and physician global assessment (PhGA) scores of disease activity, and 3) explore whether PtGA scores during disease remission are associated with future disease relapse.MethodsData from the Wegener's Granulomatosis Etanercept Trial (WGET) were used. PtGA and PhGA scores were assessed on 100‐mm visual analog scales (VAS). Presence of active disease was determined using the Birmingham Vasculitis Activity Score for WG (BVAS/WG), and remission was defined as a BVAS/WG score of 0. Disease relapse was defined as a BVAS/WG score of >0 after remission had been achieved. Discordance between PtGA and PhGA scores was defined as a difference of ≥20 points between the two measures. Mixed linear models were used in longitudinal analysis of PtGA scores.ResultsData were obtained from 180 patients in the WGET cohort, seen at a total of 1,719 study visits. The mean ± SD PtGA and PhGA disease activity scores (on 100‐mm VAS) at baseline were 64.2 ± 27.4 and 55.5 ± 23.4, respectively. PtGA–PhGA discordance occurred in 53% of patients at baseline, and this was inversely associated with newly diagnosed disease (as opposed to relapsing disease) at baseline (odds ratio 0.37, 95% confidence interval [95% CI] 0.20–0.68) but not with age, sex, or presence of renal or pulmonary disease. Patients were in disease remission during 62% of the study visits. The mean PtGA score during visits immediately prior to relapse was 4.52 points higher (95% CI 0.66–8.4) than that at other remission visits (P = 0.03).ConclusionPtGA–PhGA discordance is common in GPA. A rise in the PtGA disease activity score during times defined by physicians as periods of remission is associated with subsequent occurrence of disease relapse. These findings support the addition of PtGA as an outcome measure for GPA.